Emerging roles of PHLPP phosphatases in metabolism

키워드

참고문헌 (67)

1. Shimizu K, "SCOP, a novel gene product expressed in a circadian manner in rat suprachiasmatic nucleus", FEBS Lett, 458, pp.363~369 (1999)
2. Gao T, "PHLPP : a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth", Mol Cell, 18, pp.13~24 (2005)
3. Brognard J, "PHLiPPing the switch on Akt and protein kinase C signaling", Trends Endocrinol Metab, 19, pp.223~230 (2008)
4. Brognard J, "PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms", Mol Cell, 25, pp.917~931 (2007)
5. Baffi TR, "PHLPPing the script : emerging roles of PHLPP phosphatases in cell signaling", Annu Rev Pharmacol Toxicol, 61, pp.723~743 (2021)
6. Mendoza MC, "PHLPPing it off : phosphatases get in the Akt", Mol Cell, 25, pp.798~800 (2007)
7. Molina JR, "PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma", Oncogene, 31, pp.1264~1274 (2012)
8. Reyes G, "Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output", Proc Natl Acad Sci U S A, 111, pp.E3957~E3965 (2014)
9. Ohwada W, "Distinct intra-mitochondrial localizations of pro-survival kinases and regulation of their functions by DUSP5 and PHLPP-1", Biochim Biophys Acta Mol Basis Dis, 1866, pp.165851~ (2020)
10. Aviv Y, "Novel phosphatase PHLPP-1 regulates mitochondrial Akt activity and cardiac cell survival", Circ Res, 107, pp.448~450 (2010)
11. Brazil DP, "Ten years of protein kinase B signalling : a hard Akt to follow", Trends Biochem Sci, 26, pp.657~664 (2001)
12. Gao T, "The phosphatase PHLPP controls the cellular levels of protein kinase C", J Biol Chem, 283, pp.6300~6311 (2008)
13. Tovell H, "PHLPPing the balance : restoration of protein kinase C in cancer", Biochem J, 478, pp.341~355 (2021)
14. Liu J, "PHLPP-mediated dephosphorylation of S6K1 inhibits protein translation and cell growth", Mol Cell Biol, 31, pp.4917~4927 (2011)
15. Baffi TR, "Protein kinase C quality control by phosphatase phlpp1 unveils loss-of-function mechanism in cancer", Mol Cell, 74, pp.378~392 (2019)
16. Zhang LL, "The protein kinase C(PKC)inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer : metaanalysis of randomized controlled trials", Clin Transl Oncol, 17, pp.371~377 (2015)
17. Hsu AH, "Crosstalk between PKCalpha and PI3K", AKT signaling is tumor suppressive in the endometrium, 2018, pp.24, 655~669
18. Qiao M, "Mst1 is an interacting protein that mediates PHLPPs’ induced apoptosis", Mol Cell, 38, pp.512~523 (2010)
19. Burnett PE, "RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1", Proc Natl Acad Sci U S A, 95, pp.1432~1437 (1998)
20. Isotani S, "Immunopurified mammalian target of rapamycin phosphorylates and activates p70 S6 kinase alpha in vitro", J Biol Chem, 274, pp.34493~34498 (1999)
21. Ma XM, "Molecular mechanisms of mTOR-mediated translational control", Nat Rev Mol Cell Biol, 10, pp.307~318 (2009)
22. Wellbrock C, "The RAF proteins take centre stage", Nat Rev Mol Cell Biol, 5, pp.875~885 (2004)
23. Li X, "PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in mice", Gastroenterology, 146, pp.1301~1312 (2014)
24. Ellwood-Yen K, "Myc-driven murine prostate cancer shares molecular features with human prostate tumors", Cancer Cell, 4, pp.223~238 (2003)
25. McKeown MR, "Therapeutic strategies to inhibit MYC", Cold Spring Harb Perspect Med, 4, pp.a014266~ (2014)
26. Nowak DG, "The PHLPP2 phosphatase is a druggable driver of prostate cancer progression", J Cell Biol, 218, pp.1943~1957 (2019)
27. Chang DW, "The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals", Mol Cell Biol, 20, pp.4309~4319 (2000)
28. Hemann MT, "Evasion of the p53 tumour surveillance network by tumourderived MYC mutants", Nature, 436, pp.807~811 (2005)
29. Schwartz JP, "Studies on the hormonesensitive lipase of adipose tissue", J Lipid Res, 12, pp.553~562 (1971)
30. Kim K, "Adipocyte PHLPP2inhibition prevents obesity-induced fatty liver", Nat Commun, 12, pp.1822~ (2021)
31. Chang RM, "MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase", Hepatology, 60, pp.1251~1263 (2014)
32. Cai J, "miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer", Cancer Res, 73, pp.5402~5415 (2013)
33. Gao G, "SGT1 regulates Akt signaling by promoting beta-TrCP-dependent PHLPP1 degradation in gastric cancer cells", Mol Biol Rep, 40, pp.2947~2953 (2013)
34. Li X, "The deubiquitination enzyme USP46 functions as a tumor suppressor by controlling PHLPP-dependent attenuation of Akt signaling in colon cancer", Oncogene, 32, pp.471~478 (2013)
35. Yu Y, "PHLPP1mediates melanoma metastasis suppression through repressing AKT2 activation", Oncogene, 37, pp.2225~2236 (2018)
36. O’Hayre M, "Mechanisms and consequences of the loss of PHLPP1 phosphatase in chronic lymphocytic leukemia(CLL)", Leukemia, 26, pp.1689~1692 (2012)
37. Smith AJ, "PHLPP negatively regulates cell motility through inhibition of Akt activity and integrin expression in pancreatic cancer cells", Oncotarget, 7, pp.7801~7815 (2016)
38. Araujo AR, "Global epidemiology of non-alcoholic fatty liver disease", non-alcoholic steatohepatitis : What we need in the future, 2018, pp.38(Suppl 1), 47~51
39. Loomba R, "The global NAFLD epidemic", Nat Rev Gastroenterol Hepatol, 10, pp.686~690 (2013)
40. Younossi Z, "Global burden of NAFLD and NASH : trends, predictions, risk factors and prevention", Nat Rev Gastroenterol Hepatol, 15, pp.11~20 (2018)
41. Postic C, "Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance : lessons from genetically engineered mice", J Clin Invest, 118, pp.829~838 (2008)
42. Kim K, "Targeting of secretory proteins as a therapeutic strategy for treatment of nonalcoholic steatohepatitis(NASH)", Int J Mol Sci, 21, pp.2296~ (2020)
43. Savage DB, "Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance", Curr Opin Lipidol, 21, pp.329~336 (2010)
44. Sarbassov DD, "Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton", Curr Biol, 14, pp.1296~1302 (2004)
45. Jacinto E, "Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive", Nat Cell Biol, 6, pp.1122~1128 (2004)
46. Laplante M, "mTOR signaling in growth control and disease", Cell, 149, pp.274~293 (2012)
47. Kim K, "mTORC1-independent raptor prevents hepatic steatosis by stabilizing PHLPP2", Nat Commun, 7, pp.10255~ (2016)
48. Kim K, "Free Raptor-a novel regulator of metabolism", Cell Cycle, 15, pp.1174~1175 (2016)
49. Kim K, "Degradation of PHLPP2 by KCTD17, via a glucagon-dependent pathway, promotes hepatic steatosis", Gastroenterology, 153, pp.1568~1580 (2017)
50. Weyer C, "The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus", J Clin Invest, 104, pp.787~794 (1999)
51. Christensen AA, "The beta cell in type 2 diabetes", Curr Diab Rep, 19, pp.81~ (2019)
52. Hribal ML, "Chronic hyperglycemia impairs insulin secretion by affecting insulin receptor expression, splicing, and signaling in RIN beta cell line and human islets of Langerhans", FASEB J, 17, pp.1340~1342 (2003)
53. Ye R, "Lipotoxicity and beta cell maintenance in obesity and type 2 diabetes", J Endocr Soc, 3, pp.617~631 (2019)
54. Elghazi L, "Emerging role of protein kinase B", Akt signaling in pancreatic betacell mass and function, 2006, pp.38, 157~163
55. Hribal ML, "The phosphatase PHLPP2 plays a key role in the regulation of pancreatic beta-cell survival", Int J Endocrinol, 2020, pp.1027386~ (2020)
56. Sesti G, "Molecular mechanism of insulin resistance in type 2 diabetes mellitus : role of the insulin receptor variant forms", Diabetes Metab Res Rev, 17, pp.363~373 (2001)
57. Andreozzi F, "Increased levels of the Akt-specific phosphatase PH domain leucinerich repeat protein phosphatase(PHLPP)-1 in obese participants are associated with insulin resistance", Diabetologia, 54, pp.1879~1887 (2011)
58. Nigro C, "miR-214-dependent increase of PHLPP2 levels mediates the impairment of insulin-stimulated Akt activation in mouse aortic endothelial cells exposed to methylglyoxal", Int J Mol Sci, 19, pp.522~ (2018)
59. Sun X, "MicroRNA-181b improves glucose homeostasis and insulin sensitivity by regulating endothelial function in white adipose tissue", Circ Res, 118, pp.810~821 (2016)
60. Mathur A, "PHLPP : a putative cellular target during insulin resistance and type 2 diabetes", J Endocrinol, 233, pp.R185~R198 (2017)
61. Xiong X, "PHLPP regulates hexokinase 2-dependent glucose metabolism in colon cancer cells", Cell Death Discov, 3, pp.16103~ (2017)
62. Wu J, "Hepatic exosomederived miR-130a-3p attenuates glucose intolerance via suppressing PHLPP2 gene in adipocyte", Metabolism, 103, pp.154006~ (2020)
63. Goodyear LJ, "Exercise, glucose transport, and insulin sensitivity", Annu Rev Med, 49, pp.235~261 (1998)
64. Cozzone D, "Isoform-specific defects of insulin stimulation of Akt", protein kinase B(PKB)in skeletal muscle cells from type 2 diabetic patients, 2008, pp.51, 512~521
65. Johnson AM, "The origins and drivers of insulin resistance", Cell, 152, pp.673~684 (2013)
66. Behera S, "ERK1", 2 activated PHLPP1 induces skeletal muscle ER stress through the inhibition of a novel substrate AMPK, 2018, pp.1864, 1702~1716
67. Newton AC, "Turning off AKT : PHLPP as a drug target", Annu Rev Pharmacol Toxicol, 54, pp.537~558 (2014)

관련 논문AI추천